Journal
ADVANCED FUNCTIONAL MATERIALS
Volume 31, Issue 44, Pages -Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/adfm.202009489
Keywords
CAR T cells; cell therapy; drug delivery; immunotherapy; solid tumor
Categories
Funding
- National Institutes of Health [R01 CA234343-01A1]
- Startup Package of UCLA
- Startup Package of Zhejiang University
Ask authors/readers for more resources
CAR T cells show promise in cancer immunotherapy, but have limited clinical success in solid tumors, leading to exploration of strategies to enhance their efficacy. Altering the tumor microenvironment is crucial, with a focus on future development directions.
Chimeric antigen receptor (CAR) T cells exhibit promising results for cancer immunotherapy. However, the clinical success is still restricted to certain types of blood cancers, while in solid tumors the clinical activity is modest and potential toxicities remain a concern. There are various barriers that prevent CAR T cells from combating solid tumors. Therefore, distinct strategies have been explored to augment CAR T cell proliferative capacity, persistence, and effector function. Altering the tumor microenvironment, and in particular its physiochemical properties and immunosuppressive milieu, is of great significance to facilitate CAR T cell therapy. In this article, emerging strategies implemented to overcome the barriers of CAR T cell therapy in solid tumors are reviewed. Enhancing infiltration, activation, and persistence of CAR T cells has been addressed in several preclinical models. The future development of this field to promote innovation and clinical translation is also discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available